Xbox-Based Exergames Versus Structured Home-Based Cognitive Training for Attention and Executive Functions in Healthy Adults
NCT07809412, Not applicable, Completed, Medipol University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Xbox-Based Exergames Versus Structured Home-Based Cognitive Training for Attention and Executive Functions in Healthy Adults | ClinicalTrials.gov |
| NCT number | NCT07809412 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 20 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Medipol University | ClinicalTrials.gov |
| Conditions | Attention, Cognitive Training, Executive Functions (EF), Xbox-based Exergames, Healthy Adults | ClinicalTrials.gov |
| Interventions | Xbox-based exergames intervention, Structured home-based cognitive training | ClinicalTrials.gov |
| First posted | 2026-09-09 | ClinicalTrials.gov |
| Last updated | 2026-09-09 | ClinicalTrials.gov |
Registered outcomes 6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Standardized Mini-Mental State Examination (SMMSE) | Baseline and 1 week after completion of the 12-session intervention | The SMMSE is a brief 30-item cognitive screening tool that assesses attention, memory, orientation, language, and visuospatial abilities. The Turkish validity and reliability of the Standardized Mini-Mental State Examination (SMMSE) were established by Güngen et al. (2002). In the Turkish version, a cutoff score of 23/24 has been established for dementia. | ClinicalTrials.gov |
| Primary | d2 Test of Attention | Baseline and 1 week after completion of the 12-session intervention | The d2 Test assesses sustained and selective attention, visual scanning, and mental concentration. The d2 Test of Attention consists of 14 rows, each containing 47 characters/items. Each row includes lowercase "p" and "d" letters accompanied by one to four marks positioned above or below the letters. Participants are required to identify and mark the letter "d" accompanied by two marks within a time limit of 20 seconds for each row. Scoring is based on the total number of items processed (TN), errors of omission (E1), errors of commission (E2), and concentration performance (CP). Higher TN and CP scores indicate better attentional performance, whereas higher E1 and E2 scores indicate a greater number of errors. | ClinicalTrials.gov |
| Primary | Stroop Test | Baseline and 1 week after completion of the 12-session intervention | The Stroop Test is a neuropsychological measure of selective attention, inhibitory control, processing speed, and cognitive flexibility. The Stroop Test Çapa Version consists of three parts: Stroop A, in which participants name the colors of colored rectangles; Stroop B, in which they read color words printed in incongruent ink colors; and Stroop C, in which they name the ink color while inhibiting the tendency to read the word. Completion time is recorded for each part. In the present study, the Stroop Test Interference Time Difference was calculated by subtracting the completion time of Stroop B from that of Stroop C. The Turkish validity and reliability of the Stroop Test Çapa Version were established by Emek-Savaş et al. | ClinicalTrials.gov |
| Primary | WMS-R Digit Span Test (DST) | Baseline and 1 week after completion of the 12-session intervention | The Digit Span Subtest of the Wechsler Memory Scale-Revised (WMS-R) assesses attention, short-term memory, and working memory. It consists of Forward and Backward Digit Span conditions, in which participants repeat progressively longer digit sequences in the presented or reverse order, respectively. Each sequence length includes two trials, and the respective condition is discontinued when both trials are answered incorrectly. The Turkish standardization of the WMS-R has been established, and normative data are available for the Digit Span Test in Turkish adults aged 50-83 years. | ClinicalTrials.gov |
| Primary | The Trail Making Test (TMT) | Baseline and 1 week after completion of the 12-session intervention | The Trail Making Test (TMT) consists of two parts, TMT-A and TMT-B. TMT-A primarily assesses visual scanning, attention, and processing speed, whereas TMT-B additionally requires cognitive flexibility, set-shifting, working memory, and inhibitory control. The basic scores for TMT-A and TMT-B are completion times in seconds, with longer completion times indicating poorer performance. The Turkish validity and reliability of the Trail Making Test were established. | ClinicalTrials.gov |
| Primary | Benton Judgment of Line Orientation Test | Baseline and 1 week after completion of the 12-session intervention | The Benton Judgment of Line Orientation Test was developed by Benton et al. (1978), and its Turkish standardization was conducted within the BİLNOT battery. The Benton Judgment of Line Orientation Test (BJLOT) is a neuropsychological measure of visuospatial perception and spatial orientation. The test assesses the ability to perceive and identify angular relationships between lines and comprises five practice items followed by 30 test items. Each correct response is scored as one point, yielding a maximum score of 30, with higher scores indicating better visuospatial performance. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 6
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Cancellation Test | Primary outcome | ConductCognition |
| Digit Span Test | Primary outcome | ConductCognition |
| Line Angle Matching | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)